Fibrocell Science (FCSC) Set to Announce Earnings on Wednesday

Fibrocell Science (NASDAQ:FCSC) is scheduled to issue its quarterly earnings data before the market opens on Wednesday, May 15th. Analysts expect the company to announce earnings of ($0.33) per share for the quarter.

Fibrocell Science (NASDAQ:FCSC) last issued its earnings results on Wednesday, March 27th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.62) by $0.48. On average, analysts expect Fibrocell Science to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Shares of NASDAQ:FCSC opened at $2.25 on Friday. Fibrocell Science has a 1 year low of $1.45 and a 1 year high of $5.17. The stock has a market cap of $22.35 million, a PE ratio of -1.55 and a beta of 1.66.

FCSC has been the subject of a number of research reports. Zacks Investment Research upgraded Fibrocell Science from a “hold” rating to a “buy” rating and set a $2.25 target price for the company in a report on Wednesday, January 16th. HC Wainwright reiterated a “buy” rating and set a $22.00 target price on shares of Fibrocell Science in a report on Thursday, March 28th.

COPYRIGHT VIOLATION WARNING: This news story was originally reported by American Banking News and is owned by of American Banking News. If you are accessing this news story on another website, it was copied illegally and republished in violation of US and international trademark and copyright legislation. The original version of this news story can be accessed at https://www.americanbankingnews.com/2019/05/10/fibrocell-science-fcsc-set-to-announce-earnings-on-wednesday.html.

Fibrocell Science Company Profile

Fibrocell Science, Inc, an autologous cell and gene therapy company, focuses on discovering and developing therapies for diseases affecting the skin and connective tissues in the United States. The company's gene therapy product candidates include FCX-007 that is in Phase I/II clinical trials to treat recessive dystrophic epidermolysis bullosa; FCX-013, a gene therapy for localized scleroderma; and gene-therapy program that is in research phase to arthritis and related conditions.

Featured Article: Calculate Your Return on Investment (ROI)

Earnings History for Fibrocell Science (NASDAQ:FCSC)

Receive News & Ratings for Fibrocell Science Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fibrocell Science and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply